Candidates: Treatments to be selected
Types: Antiviral compounds
Status: Scripps Research said April 16 it has established an international network of collaborating scientific laboratories to identify antiviral compounds for development against COVID-19, using the ReFRAME screening library of more than 14,000 molecules assembled by combining three databases (Clarivate Integrity, GVK Excelra GoStar and Citeline Pharmaprojects) to facilitate drug repurposing.
Researchers at Calibr, the drug development division of Scripps Research, have teamed up with scientists from the U.S., Europe and Asia to screen the vast collection of compounds for individual drugs or combinations that may be effective in treating people exposed to COVID-19. ReFRAME was established by Calibr in 2018 with support from the Bill & Melinda Gates Foundation, and is being applied as part of the COVID-19 Therapeutics Accelerator, launched in March with $125 million in seed funding by the Gates Foundation, Wellcome, and Mastercard.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data.
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types:
● ANTIVIRAL
● VAX
● ANTIBODY
● RNA
